Literature DB >> 8322236

Psychiatric and social aspects of brittle asthma.

G M Garden1, J G Ayres.   

Abstract

BACKGROUND: Many studies have shown that emotional factors play a part in asthma, but few have compared patients with differing severities of asthma. It was our impression that patients with "brittle" asthma (BA; more than 40% diurnal variation in peak flow on 15 or more days a month over a period of at least six months, and persistent symptoms despite multiple drug treatment) had greater psychosocial morbidity than asthmatic patients with less variable asthma.
METHODS: Twenty patients with BA and a control group of less severe asthmatic subjects matched for age, sex, and duration of illness were asked to complete the General Health Questionnaire (GHQ), a screening test for psychiatric disorders, the Eysenck Personality Inventory which measures extraversion and neuroticism, and to participate in a life events interview and a structured clinical interview (SCID) to diagnose psychiatric disorder.
RESULTS: The mean (SD) age was 45.6 (12.3) years for the BA group, and 45.7 (13.1) years for the control group. All patients were receiving inhaled steroids and regular beta 2 agonists; nine patients with BA but no control patients were taking oral steroids, and 12 of the patients with BA but no controls were receiving beta 2 agonists by subcutaneous infusion or injection. Eight of the patients with BA scored more than 11 on the GHQ compared with five of the control group (NS). Significantly more subjects with BA (12/20) than controls (5/20) had intercurrent or past psychiatric disorder, and 7/20 subjects with BA had a lifetime history of anxiety disorder compared with 3/20 controls. Life events analysis showed no overall difference in the total number, but the patients with BA had significantly more life events related to asthma. There was no difference in personality profiles between the two groups.
CONCLUSIONS: The results suggest that patients with "brittle" asthma have greater psychiatric morbidity than those with less severe asthma, but that their personality profiles and overall life event experiences are similar.

Entities:  

Mesh:

Year:  1993        PMID: 8322236      PMCID: PMC464502          DOI: 10.1136/thx.48.5.501

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

1.  Use of the general health questionnaire in clinical work.

Authors:  D Goldberg
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-08

2.  Long term treatment of severe asthma with subcutaneous terbutaline.

Authors:  B R O'Driscoll; S P Ruffles; J G Ayres; G M Cochrane
Journal:  Br J Dis Chest       Date:  1988-10

3.  Psychiatric morbidity in patients with life-threatening asthma: initial report of a controlled study.

Authors:  P M Yellowlees; S Haynes; N Potts; R E Ruffin
Journal:  Med J Aust       Date:  1988-09-05       Impact factor: 7.738

4.  Bronchial asthma: lack of relationships between allergic factors, illness severity and psychosocial variables in adult patients attending an asthma clinic.

Authors:  B J Spittle; M R Sears
Journal:  Psychol Med       Date:  1984-11       Impact factor: 7.723

5.  Controlled evaluation of the effects of patient education on asthma morbidity in general practice.

Authors:  S Hilton; B Sibbald; H R Anderson; P Freeling
Journal:  Lancet       Date:  1986-01-04       Impact factor: 79.321

6.  Psychological defenses and coping styles in patients following a life-threatening attack of asthma.

Authors:  P M Yellowlees; R E Ruffin
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

7.  Patient self care in acute asthma.

Authors:  B Sibbald
Journal:  Thorax       Date:  1989-02       Impact factor: 9.139

8.  A case-control study of deaths from asthma.

Authors:  H H Rea; R Scragg; R Jackson; R Beaglehole; J Fenwick; D C Sutherland
Journal:  Thorax       Date:  1986-11       Impact factor: 9.139

9.  Psychiatric morbidity and social problems in patients with insulin-dependent diabetes mellitus.

Authors:  G Wilkinson; D Q Borsey; P Leslie; R W Newton; C Lind; C B Ballinger
Journal:  Br J Psychiatry       Date:  1988-07       Impact factor: 9.319

10.  Relationship between psychosocial factors and asthma morbidity.

Authors:  B Sibbald; P White; C Pharoah; P Freeling; H R Anderson
Journal:  Fam Pract       Date:  1988-03       Impact factor: 2.267

View more
  12 in total

1.  Asthma: wheezing, woes, and worries.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2008-10

Review 2.  Psychosocial aspects of asthma in adults.

Authors:  B D Harrison
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

3.  Pseudo-steroid resistant asthma.

Authors:  P S Thomas; D M Geddes; P J Barnes
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

4.  Emotional aspects of asthma.

Authors:  N More; N Singh; A Athawale; A C Shah
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

5.  Dietary antioxidants and magnesium in type 1 brittle asthma: a case control study.

Authors:  J C Baker; W S Tunnicliffe; R C Duncanson; J G Ayres
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 6.  Asthma mortality and antipsychotic or sedative use. What is the link?

Authors:  K S Joseph
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

7.  Case-control study of severe life threatening asthma (SLTA) in adults: psychological factors.

Authors:  J Kolbe; W Fergusson; M Vamos; J Garrett
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

8.  Asthma: the psychosocial impact among a sample of south western Nigerians.

Authors:  Gregory E Erhabor; Folake Kuteyi; Femi Obembe
Journal:  J Natl Med Assoc       Date:  2002-11       Impact factor: 1.798

Review 9.  Brittle asthma.

Authors:  J G Ayres; J F Miles; P J Barnes
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

10.  Rapid onset asthma: a severe but uncommon manifestation.

Authors:  J Kolbe; W Fergusson; J Garrett
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.